Form 4: Stoke Therapeutics GC Sells Shares After Vesting

Stoke Therapeutics' General Counsel, Jonathan Allan, reported the exercise of performance stock units and subsequent sales of common stock, including tax-related dispositions and sales under a 10b5-1 plan.

Summary

• Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported multiple transactions involving the company's common stock.
• On December 3, 2025, Allan acquired 6,000 shares of common stock through the exercise of Performance Stock Units (PSUs) at a $0 exercise price, following the vesting of the awards.
• A total of 2,022 shares were sold on December 4-5, 2025, at weighted average prices ranging from $30.7635 to $31.3304. These sales were mandated by the Issuer to satisfy tax withholding liabilities associated with the vesting and settlement of restricted stock units.
• An additional 7,781 shares were sold on December 5, 2025, at weighted average prices of $31.0828 and $31.7597. These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Allan on December 12, 2024.
• Following these reported transactions, Allan beneficially owns 15,809 shares of Stoke Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including sales for tax purposes and under a pre-arranged trading plan. These are common events for executives with equity compensation and do not inherently indicate positive or negative sentiment about the company's prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing reports routine insider transactions for an executive at a biotechnology company. Such filings are common in the industry as executives manage their equity compensation and personal finances, often through pre-arranged trading plans.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even if pre-planned or for tax purposes, slightly increases the float and could be perceived differently by various investors, though these are routine events.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions by the General Counsel, including the exercise of vested equity awards and subsequent sales to cover tax obligations and under a pre-established 10b5-1 trading plan. These transactions are common for executives managing their compensation and do not provide new fundamental information about Stoke Therapeutics' operational performance or future prospects. Therefore, the filing itself does not warrant a change in investment recommendation; a 'hold' stance is maintained pending further substantive company news.

Keywords

Stoke Therapeutics, STOK, Insider Trading, Form 4, Jonathan Allan, Stock Sale, Equity Vesting, 10b5-1 Plan, General Counsel, Biotechnology